A Short-Period Therapy with Subcutaneous Low-Dose IL-2 Plus High-Dose Melatonin to Correct Advanced Cancer-Related Lymphocytopenia: Possible Impact on the Survival Time: Figure 1

Figure 1: Lymphocyte, monocyte, and lymphocyte-to-monocyte ratio (LMR) under IL2.